Metformin Dosing Guidelines for Type 2 Diabetes Management

Standard Dosing and Maximum Dose

The maximum dose of metformin is 2000 mg daily for most patients, with a typical target maintenance dose of 1000 mg twice daily, according to the American College of Clinical Endocrinologists 1

The American Diabetes Association recommends increasing metformin by 500 mg increments every 7 days until reaching the target dose of 2000 mg daily, to minimize gastrointestinal side effects, as stated by the American Diabetes Association 1
For immediate-release formulation, the dosing protocol is to start at 500 mg once or twice daily with meals, and increase by 500 mg weekly until reaching 1000 mg twice daily, as recommended by the Pediatric Endocrine Society 2, 1
For extended-release formulation, the dosing protocol is to start at 500 mg once daily with evening meal, and increase by 500 mg weekly to a maximum of 2000 mg once daily, according to the American College of Clinical Endocrinologists 1

No dose adjustment is needed if the estimated glomerular filtration rate (eGFR) is ≥60 mL/min/1.73 m², and the dose can be increased to 2000 mg daily, as stated by the National Kidney Foundation 1, 3
If the eGFR is 45-59 mL/min/1.73 m², caution should be used and the maximum dose should be limited to 1000 mg daily, according to the American College of Clinical Endocrinologists 1
If the eGFR is 30-44 mL/min/1.73 m², the maximum dose is 1000 mg daily, and the dose should not be increased beyond the current dose, as recommended by the National Kidney Foundation 1
If the eGFR is <30 mL/min/1.73 m², metformin should be discontinued immediately due to the risk of lactic acidosis, as stated by the Endocrine Society 4, 3

The dose should not be increased in patients with acute kidney injury, hypoxia, or shock, due to the risk of lactic acidosis, according to the American College of Clinical Endocrinologists 4, 5
The dose should not be increased in patients with active sepsis or significant infection with metabolic instability, as stated by the Infectious Diseases Society of America 4
The dose should not be increased in patients with impaired hepatic function or alcoholism, due to impaired lactate clearance, according to the American Association for the Study of Liver Diseases 4
The dose should not be increased in patients with an upcoming iodinated contrast procedure and an eGFR <60 mL/min/1.73 m², as recommended by the National Kidney Foundation 4

Fasting blood glucose should be monitored regularly during titration to assess the effectiveness of the dose, according to the American Diabetes Association 1
The eGFR should be checked at least annually if ≥60 mL/min/1.73 m², or every 3-6 months if <60 mL/min/1.73 m², as stated by the National Kidney Foundation 1, 3
If glycemic targets are not met after 3 months at the maximum tolerated dose, a second agent such as an SGLT2 inhibitor or GLP-1 receptor agonist should be considered, according to the American College of Clinical Endocrinologists 1